Omega Therapeutics Announces Updates to its Board of Directors
Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed...
Pharmaceutical
Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development...
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
19.3 month significant survival difference for CNM-Au8® treated participants versus placebo52% significant decreased risk of ALS clinical worsening events Over...
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives...
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed...
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD)...
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused...
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
Maximizing global leadership of SYFOVRE in geographic atrophy (GA)Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3GFocusing...
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the...
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back...
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Bioventure Bioventure logo Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureAlvotech (NASDAQ:...
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureREYKJAVIK, Iceland and DUBAI,...
Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung,...
Red Light Holland Reports First Quarter 2024 Results
Cash balance of $17.5 million as at June 30, 2023Revenue of $1.2 million (vs 2022: $0.8 million, an increase of...
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC")...
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIALNEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / August 29, 2023...
Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC / ACCESSWIRE /...
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3...